河北医科大学学报 ›› 2021, Vol. 42 ›› Issue (2): 140-144.doi: 10.3969/j.issn.1007-3205.2021.02.004

• • 上一篇    下一篇

利拉鲁肽联合替格瑞洛对2型糖尿病合并冠心病血清Vaspin及Ghrelin的影响

  

  1. 江苏省太仓市第一人民医院内分泌科，江苏 太仓 215400
  • 出版日期:2021-02-25 发布日期:2021-03-09
  • 作者简介:杨熹（1989-），男，江苏太仓人，江苏省太仓市第一人民医院主治医师，医学硕士，从事内分泌科疾病诊治研究。

Effects of liraglutide combined with ticagrelor on serum Vaspinand Ghrelin in patients with type 2 diabetes mellitus and coronary heart disease

  1. Department of Endocrinology, the First People′s Hospital of Taicang City, Jiangsu Province, Taicang 215400, China
  • Online:2021-02-25 Published:2021-03-09

HTML

PDF (PC)

178

摘要： 目的  探讨利拉鲁肽与替格瑞洛联合应用治疗2型糖尿病合并冠心病临床疗效及患者血清内脏脂肪组织特异性丝氨酸蛋白酶抑制因子（visceral adipose tissue-derived serine protease inhibitor,Vaspin）和生长激素释放肽（Ghrelin）的影响。
方法  选取114例2型糖尿病合并冠心病患者，采用随机数字分为对照组与观察组，每组57例，对照组给予替格瑞洛和盐酸二甲双胍，观察组给予替格瑞洛和利拉鲁肽。比较两组临床疗效，治疗前后的血脂、血糖、心功能，血清内皮细胞相关因子Vaspin和Ghrelin的水平以及不良反应的发生情况。
结果  观察组有效率显著高于对照组（P＜0.05）。治疗后，两组血糖水平较治疗前均明显降低（P＜0.05），两组血糖水平比较差异无统计学意义（P＞0.05）。治疗后，对照组左心室射血分数（left ventricular eject fraction,LVEF）、左心室舒张末期内径（left ventricular end diastolic dimension，LVEDD）、舒张早期/舒张晚期二尖瓣血流速度的比值（early/late diastolic mitral flow velocity ratio，E/A）的水平较治疗前均有改善，观察组心功能各项指标较治疗前均有改善，观察组心功能各项指标较对照组改善更明显（P＜0.05）。治疗后，两组Ghrelin水平均明显高于治疗前，Vaspin水平明显低于治疗前，观察组Vaspin和Ghrelin水平较对照组改善明显（P＜0.05）。
结论  利拉鲁肽能够有效调节血糖及血清内皮细胞相关因子Vaspin和Ghrelin的水平，改善血管内皮功能和心功能。


关键词: 糖尿病, 2型；冠心病；利拉鲁肽；替格瑞洛

Abstract: Objective  To explore the clinical effect of combined use of liraglutide and ticagrelor in the treatment of type 2 diabetes mellitus(T2DM) complicated by coronary heart disease(CHD) and its effect on serum visceral adipose tissue-derived serine protease inhibitor(Vaspin) and growth hormone releasing peptide Ghrelin. 
Methods  A total of 114 patients with T2DM and CHD diagnosed in our hospital were selected and divided into a control group(n=57) and an observation group(n=57) by random number grouping. The control group was given ticagrelor and metformin hydrochloride, and the observation group was given ticagrelor and liraglutide. The clinical efficacy, blood lipids, blood glucose, cardiac function, levels of serum endothelial cell-associated factors Vaspin and Ghrelin before and after treatment and the incidence of adverse reactions were compared between two groups. 
Results  The effective rate of the observation group was significantly higher than that of the control group(P＜0.05). After treatment, the blood glucose levels of the two groups were significantly lower than before treatment(P＜0.05), and there was no significant difference in blood glucose levels between two groups(P＞0.05). After treatment, the levels of left ventricular eject fraction(LVEF), left ventricular end diastolic dimension(LVEDD), and early/late diastolic mitral flow velocity ratio（E/A） in the control group were improved compared to before treatment, and all indicators of heart function in the observation group were improved compared with before treatment. The indicators of heart function in the observation group improved more significantly than those in the control group(P＜0.05). After treatment, the levels of Ghrelin in the two groups were significantly higher than those before treatment, and the levels of Vaspin were significantly lower than those before treatment. The levels of Vaspin and Ghrelin in the observation group were significantly improved compared with the control group(P＜0.05). 
Conclusion  Liraglutide can effectively regulate blood glucose and serum endothelial cell-related factors Vaspin and Ghrelin levels, and improve vascular endothelial function and cardiac function.


Key words: diabetes melltns, type 2； , coronary heart disease； lillaluin； tigrello

版权所有 © 《河北医科大学学报》编辑部
本系统由北京玛格泰克科技发展有限公司设计开发